HK1220193A1 - 酪氨酸激酶抑制劑及其鹽的晶體形式 - Google Patents

酪氨酸激酶抑制劑及其鹽的晶體形式

Info

Publication number
HK1220193A1
HK1220193A1 HK16108270.6A HK16108270A HK1220193A1 HK 1220193 A1 HK1220193 A1 HK 1220193A1 HK 16108270 A HK16108270 A HK 16108270A HK 1220193 A1 HK1220193 A1 HK 1220193A1
Authority
HK
Hong Kong
Prior art keywords
salts
tyrosine kinase
kinase inhibitors
crystalline forms
crystalline
Prior art date
Application number
HK16108270.6A
Other languages
English (en)
Inventor
Jay Jie-Qiang Wu
Ling Wang
Original Assignee
Mundipharma Int Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mundipharma Int Corp Ltd filed Critical Mundipharma Int Corp Ltd
Publication of HK1220193A1 publication Critical patent/HK1220193A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK16108270.6A 2013-03-15 2016-07-14 酪氨酸激酶抑制劑及其鹽的晶體形式 HK1220193A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361801112P 2013-03-15 2013-03-15
PCT/US2014/027591 WO2014152663A1 (en) 2013-03-15 2014-03-14 Crystalline forms of tyrosine kinase inhibitors and their salts

Publications (1)

Publication Number Publication Date
HK1220193A1 true HK1220193A1 (zh) 2017-04-28

Family

ID=51529961

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108270.6A HK1220193A1 (zh) 2013-03-15 2016-07-14 酪氨酸激酶抑制劑及其鹽的晶體形式

Country Status (23)

Country Link
US (5) US8999992B2 (zh)
EP (1) EP2970148A4 (zh)
JP (1) JP2016513704A (zh)
KR (1) KR20150142688A (zh)
CN (1) CN105377821A (zh)
AU (1) AU2014239254B2 (zh)
BR (1) BR112015022631A2 (zh)
CA (1) CA2904403A1 (zh)
CL (1) CL2015002593A1 (zh)
CR (1) CR20150560A (zh)
EA (1) EA201591684A1 (zh)
GT (1) GT201500292A (zh)
HK (1) HK1220193A1 (zh)
MX (1) MX2015012403A (zh)
NI (1) NI201500139A (zh)
PE (1) PE20151884A1 (zh)
PH (1) PH12015502110A1 (zh)
SG (2) SG10201707484UA (zh)
SV (1) SV2015005074A (zh)
TN (1) TN2015000407A1 (zh)
UA (1) UA116466C2 (zh)
WO (1) WO2014152663A1 (zh)
ZA (1) ZA201507154B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2586212C2 (ru) 2008-12-08 2016-06-10 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
AU2015318324A1 (en) * 2014-09-17 2017-04-06 Mundipharma International Corporation Limited Crystalline forms of tyrosine kinase inhibitors and their salts
WO2017027465A1 (en) * 2015-08-07 2017-02-16 Purdue Pharma L.P. Process of preparing tyrosine kinase inhibitor
MA50398B1 (fr) 2017-10-18 2021-10-29 Incyte Corp Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
SG11202102224UA (en) 2018-09-05 2021-04-29 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
IL297492A (en) 2020-05-19 2022-12-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
RU2065438C1 (ru) 1993-12-22 1996-08-20 Институт химии природного органического сырья СО РАН Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US5998463A (en) 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
US6476032B2 (en) 1998-12-17 2002-11-05 Wyeth 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
PL352680A1 (en) 1999-06-03 2003-09-08 Knoll Gmbh Benzothiazinone and benzoxazinone compounds
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
DE60215682T2 (de) 2001-09-27 2007-09-06 Smithkline Beecham Corp. AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
KR20030095729A (ko) 2002-06-14 2003-12-24 크리스탈지노믹스(주) 2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5Ｈ-티아졸로[3,2-ａ]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1Ｂ 활성 억제용 약학 조성물
JP4584713B2 (ja) 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
EP2033654B1 (en) 2003-04-16 2012-05-16 Bristol-Myers Squibb Company Process for resolving a mixture of alkyl ester enantiomers using an enzyme
EP1663962A4 (en) 2003-08-22 2007-08-22 Dendreon Corp COMPOSITIONS AND METHODS FOR TREATING A DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION
WO2008021463A2 (en) 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
MXPA06011463A (es) 2004-04-07 2007-04-25 Rinat Neuroscience Corp Metodos para tratar dolor por cancer de hueso al administrar un antagonista de factor de crecimiento de nervio.
WO2006007864A1 (en) 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
MX2007008771A (es) 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
FR2881138B1 (fr) 2005-01-27 2007-03-02 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
JP5191155B2 (ja) 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
JP2007303392A (ja) 2006-05-11 2007-11-22 Honda Motor Co Ltd 気体燃料内燃機関の制御装置
WO2008053863A1 (fr) 2006-10-30 2008-05-08 Santen Pharmaceutical Co., Ltd. Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one
EP2114948B1 (en) 2006-12-28 2014-06-25 AbbVie Inc. Inhibitors of poly(adp-ribose)polymerase
EP2176241B1 (en) 2007-08-17 2015-12-23 Hetero Drugs Limited A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
KR101192231B1 (ko) 2007-11-16 2012-10-17 홀린워스 펀드, 엘.엘.씨. 메타물질 구조에 기반한 필터 및 필터 설계 방법
RU2586212C2 (ru) 2008-12-08 2016-06-10 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
EP2239256A1 (en) * 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
US20130158264A1 (en) 2010-06-23 2013-06-20 Arlindo L. Castelhano Polymorphs of OSI-906
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9376406B2 (en) 2011-03-03 2016-06-28 Indiana University Research And Technology Corporation uPAR-uPA interaction inhibitors and methods for treating cancer
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
AU2015318324A1 (en) 2014-09-17 2017-04-06 Mundipharma International Corporation Limited Crystalline forms of tyrosine kinase inhibitors and their salts

Also Published As

Publication number Publication date
AU2014239254B2 (en) 2018-06-28
US20150174124A1 (en) 2015-06-25
EP2970148A1 (en) 2016-01-20
CR20150560A (es) 2016-08-31
US20170105990A1 (en) 2017-04-20
BR112015022631A2 (pt) 2017-12-19
KR20150142688A (ko) 2015-12-22
US20180057469A1 (en) 2018-03-01
TN2015000407A1 (en) 2017-01-03
NI201500139A (es) 2016-02-16
US20140275113A1 (en) 2014-09-18
EA201591684A1 (ru) 2016-02-29
PE20151884A1 (es) 2016-01-08
US8999992B2 (en) 2015-04-07
SG11201507516XA (en) 2015-10-29
SV2015005074A (es) 2017-07-19
GT201500292A (es) 2019-07-29
PH12015502110A1 (en) 2016-01-11
US10124002B2 (en) 2018-11-13
AU2014239254A1 (en) 2015-10-15
SG10201707484UA (en) 2017-10-30
JP2016513704A (ja) 2016-05-16
ZA201507154B (en) 2017-09-27
UA116466C2 (uk) 2018-03-26
MX2015012403A (es) 2016-04-04
CN105377821A (zh) 2016-03-02
US9993473B2 (en) 2018-06-12
CA2904403A1 (en) 2014-09-25
US20160002182A1 (en) 2016-01-07
US9388146B2 (en) 2016-07-12
WO2014152663A1 (en) 2014-09-25
EP2970148A4 (en) 2016-10-12
US9718794B2 (en) 2017-08-01
CL2015002593A1 (es) 2016-08-19
US20170001969A9 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
HK1216315A1 (zh) 表皮生長因子受體的活化突變形式的喹唑啉抑制劑
HK1219421A1 (zh) 激酶抑制劑的組合及其用途
SG11201600062RA (en) Pyrimidine derivatives as kinase inhibitors
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1220193A1 (zh) 酪氨酸激酶抑制劑及其鹽的晶體形式
HK1214813A1 (zh) 激酶抑制劑
ZA201500471B (en) Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof
HK1210461A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1217695A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
HK1210779A1 (zh) 酪氨酸激酶抑制劑
HK1218416A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
IL251197A0 (en) The crystal forms of tyrosine kinase inhibitors and their salts
EP2968995A4 (en) INHIBITORS OF LRRK2 KINASE ACTIVITY
EP2988738A4 (en) THERAPEUTIC APPLICATIONS OF KINASEHEMMERN
HK1215855A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1222644A1 (zh) 種可作為表皮生長因子受體激酶抑制劑的鹽式
HK1226070B (zh) 酪氨酸蛋白激酶抑制劑
HK1218394A1 (zh) 酪氨酸蛋白激酶抑制劑
HK1222386A1 (zh) 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺
HK1214257A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
GB201323021D0 (en) Use of kinase inhibitors
GB201321227D0 (en) Use of kinase inhibitors
GB201309603D0 (en) Novel compounds and their use as kinase inhibitors
GB201305741D0 (en) Novel compounds and their use as kinase inhibitors
GB201307155D0 (en) Kinase inhibitors